Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SUPER 2 (NCT04998032), phase 3 stage

SUPER 2 (NCT04998032), phase 3 stage

Efsubaglutide alfa (supaglutide) · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Efsubaglutide alfa (supaglutide)
Population
t2d
Official title
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)
Sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase
2/3
Registry status
completed · 2021-10 → 2023-06
Participants
620
Duration
12, 24 weeks
Registry
NCT04998032

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
3 mg QWt2d china24171——−1.8 vs −0.7——7.6 vs 4.09.9 vs 1.7——press release
1 mg QWt2d china12120——−1.1——————press release
3 mg QWt2d china12120——−1.4——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (5)
  • 3 mg QW · hba1c · publication
    At week 24 in phase 3, HbA1c decreased by 1.80% with Efsubaglutide 3 mg versus 0.74% with placebo
  • 3 mg QW · vomiting · publication
    including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
  • 3 mg QW · nausea · publication
    including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
  • 1 mg QW · hba1c · publication
    At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg
  • 3 mg QW · hba1c · publication
    At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SUPER 2 (NCT04998032), phase 3 stage. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/super-2-phase-3-stage/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.